The predictive function of PD-L1 expression and other immunoarchitectural features of pretreatment tumors will be specifically addressed in ongoing phase II and III trials on PD-1/PD-L1 pathway inhibitors in different solid tumors, including melanoma and NSCLC. Here, PDCD1 is linked to melanoma.